For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical developmen 16 April 2021
Californian ageing specialist CohBar (Nasdaq: CWBR) is focused on treating mitochondrial diseases, but chief executive Steven Engle doesn’t rule out offering a 23 March 2021
While much of the world’s focus is on what pharma can do to end the coronavirus pandemic, the rest of the industry is continuing its work ensuring innovative me 17 November 2020
At the annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, Johnson & Johnson’s pharma arm Janssen hopes to raise the bar 17 September 2020
Bringing a cancer treatment to patients that involves breakthrough technology and an enlightened approach from regulators, health technology assessment (HTA) ag 18 August 2020
A collaborative framework in which national and foreign actors converge allows the people of Uruguay access to a wide range of medicines, and the resilience of 23 July 2020
While vaccine developers including Moderna Therapeutics and AstraZeneca have reported promising results from their COVID-19 programs, the world urgently needs b 17 July 2020
There was a time when executives at Teva Pharmaceutical Industries thought that their product might be the third anti-calcitonin gene-related peptide (CGRP) dru 29 April 2020
Located at the heart of the Cambridge biotech cluster in Massachusetts, Kymera Therapeutics is exploring the notion that targeted protein degradation could prov 9 March 2020
Scientists have shown that inflammatory disease in the body is associated with an increased risk of Alzheimer’s, something that is central to the approach taken 17 February 2020
As biotech companies making themselves eligible to a big pharma buyout go, Imugene appears to tick a lot of the boxes – but the proof of the pudding will come w 24 January 2020
In partnership with Samsung Bioepis – a joint venture in which it recently upped its stake in to 49.9% - the US biotech company Biogen has been an undisputed le 2 January 2020
Biosimilars manufacturers can get a bad rap. Derided as offering mere copycats, piggybacking off the success of true innovators, companies such as South Korea's 6 December 2019
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.